Capital Access Window
LONDON and PHILADELPHIA – September 30, 2026 – Avacta Therapeutics (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, announces its intention to utilise AIM’s new Capital Access Window rule in connection with a proposed equity capital raise (the “Proposed Fundraise”).
Intention to undertake an equity capital raise
Avacta recently announced clinical proof of mechanism for AVA6103, its next-generation controlled-release pre|CISION® peptide-drug conjugate (PDC) platform in the ongoing phase 1 FOCUS-01 trial. The datasets presented by the Company greatly increases the Board’s confidence that the safety profile, tumor selectivity and antitumor efficacy observed in the preclinical studies of AVA6103 will translate into the clinic.
As previously announced the Company currently has a cash runway into early Q1 2027 and is continuing discussions with potential partners on the Next Gen assets. With the clinical proof of mechanism for AVA6103 enhancing Avacta’s partnering position, the Company is progressing an equity fundraise to increase its cash runway further into 2027 to further strengthen this position.
These additional funds would allow Avacta to progress AVA6103 (first Next Gen pre|CISION asset), continue the trials of AVA6000 (pre|CISION Gen One) and continue AVA6207 (second Next Gen asset, dual payloads) towards Phase 1 trials.
Capital Access Window
Following the updates to the AIM Rules for Companies announced in August 2026, to support the Proposed Fundraise, the Company will enter a Capital Access Window with effect from 7.30am BST today. This is a voluntary temporary pause in the trading of the Company’s shares on AIM to make it easier to reach a broader range of investors, and to provide pricing stability during a fundraise. The Capital Access Window will remain in place until a further announcement is made detailing the results of the Proposed Fundraise.
The Company will host an investor presentation of the Interim Results in the near future via Investor Meet. Details will be forthcoming.
This announcement does not constitute an offer of securities in any jurisdiction. The Proposed Fundraise, if implemented, will be the subject of further announcements, which will include the material terms and conditions of the Proposed Fundraise.